Stevanato Group Is Future-Proofing Pharma with AI-Pricing, Biologics & A New Indiana Plant But Is  It Enough? 

Stevanato Group’s first quarter of fiscal 2025 results showcase both strengths and challenges in their operational execution, highlighting the complexities of navigating a global manufacturing and business environment. The company’s total revenue increased by 9% to EUR 256.6 million compared to the prior year, primarily driven by the Biopharmaceutical and Diagnostics Solutions (BDS) segment, which saw an 11% revenue increase. The Engineering Segment experienced a 4% revenue decline, primarily due to legacy projects impacting profitability.